Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction

Ali Javaheri; Jeremy C. Allegood; L. Ashley Cowart; Julio A. Chirinos

doi:10.1016/j.jacc.2020.02.062

Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction

Ali Javaheri
, Jeremy C. Allegood
, L. Ashley Cowart
, Julio A. Chirinos

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2273-2275
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	75
Issue number	17
DOIs	https://doi.org/10.1016/j.jacc.2020.02.062
State	Published - May 5 2020

Access to Document

10.1016/j.jacc.2020.02.062

Cite this

@article{98412b6b1bfa469b8e48c5b369bcd052,

title = "Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction",

author = "Ali Javaheri and Allegood, \{Jeremy C.\} and Cowart, \{L. Ashley\} and Chirinos, \{Julio A.\}",

note = "Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073–01A1 (Dr. Chirinos), R01 HL 121510–01A1 (Dr. Chirinos), and 5-R21-AG-043802–02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262–01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510–01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874–01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH–National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH. Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073?01A1 (Dr. Chirinos), R01 HL 121510?01A1 (Dr. Chirinos), and 5-R21-AG-043802?02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262?01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510?01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874?01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH?National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH.",

year = "2020",

month = may,

day = "5",

doi = "10.1016/j.jacc.2020.02.062",

language = "English",

volume = "75",

pages = "2273--2275",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

number = "17",

}

TY - JOUR

T1 - Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction

AU - Javaheri, Ali

AU - Allegood, Jeremy C.

AU - Cowart, L. Ashley

AU - Chirinos, Julio A.

N1 - Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073–01A1 (Dr. Chirinos), R01 HL 121510–01A1 (Dr. Chirinos), and 5-R21-AG-043802–02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262–01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510–01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874–01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH–National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH. Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073?01A1 (Dr. Chirinos), R01 HL 121510?01A1 (Dr. Chirinos), and 5-R21-AG-043802?02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262?01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510?01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874?01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH?National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH.

PY - 2020/5/5

Y1 - 2020/5/5

UR - https://www.scopus.com/pages/publications/85083523998

U2 - 10.1016/j.jacc.2020.02.062

DO - 10.1016/j.jacc.2020.02.062

M3 - Letter

C2 - 32354389

AN - SCOPUS:85083523998

SN - 0735-1097

VL - 75

SP - 2273

EP - 2275

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 17

ER -

Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction

Access to Document

Other files and links

Cite this